Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | HPGD | P15428 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | SIRT2 | Q8IXJ6 | 7/20 | 0.55 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.54 |
| ▸ | SIRT1 | Q96EB6 | 4/20 | 0.52 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.51 |
| ▸ | PRCP | P42785 | 1/20 | 0.48 |
| ▸ | FAAH | O00519 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10030730 | 0.89 | HPGD (0.54) | HPGDSIRT2EPHX2FAAH | |
| SCHEMBL20029050 | 0.88 | EPHX2 (0.62) | MEN1HPGDKMT2AALDH1A1SIRT2 | |
| SCHEMBL10030733 | 0.88 | HPGD (0.47) | MEN1HPGDKMT2AALDH1A1SIRT2 | |
| SCHEMBL27688463 | 0.87 | EPHX2 (0.59) | MEN1HPGDKMT2AALDH1A1SIRT2 | |
| SCHEMBL20960123 | 0.84 | MEN1 (0.54) | MEN1HPGDKMT2AALDH1A1SIRT2 | |
| SCHEMBL10030729 | 0.84 | HPGD (0.56) | MEN1HPGDKMT2AEPHX2 | |
| SCHEMBL19617998 | 0.84 | HPGD (0.56) | MEN1HPGDKMT2AEPHX2 | |
| SCHEMBL18743946 | 0.84 | HPGD (0.58) | MEN1HPGDKMT2AALDH1A1SIRT2 | |
| SCHEMBL10030728 | 0.84 | EPHX2 (0.50) | HPGDSIRT2EPHX2SIRT1 | |
| SCHEMBL17589268 | 0.83 | HPGD (0.52) | MEN1HPGDKMT2AALDH1A1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170210922-A1 | 3D PRINTING SYSTEM COMPRISING SOLID BUILD INK COMPRISING COLORANT | XEROX CORPORATION | 2017-07-27 | — | — | US | disclosed |
| US-20170210922-A1 | 3D PRINTING SYSTEM COMPRISING SOLID BUILD INK COMPRISING COLORANT | XEROX CORPORATION | 2017-07-27 | — | — | US | disclosed |
| US-9676952-B2 | 3D printing system comprising solid build ink comprising colorant | XEROX CORPORATION (US) | 2017-06-13 | — | — | US | disclosed |
| US-9676952-B2 | 3D printing system comprising solid build ink comprising colorant | XEROX CORPORATION (US) | 2017-06-13 | — | — | US | disclosed |
| US-20160244628-A1 | 3D PRINTING SYSTEM COMPRISING SOLID BUILD INK COMPRISING COLORANT | XEROX CORPORATION | 2016-08-25 | — | — | US | disclosed |
| US-20160244628-A1 | 3D PRINTING SYSTEM COMPRISING SOLID BUILD INK COMPRISING COLORANT | XEROX CORPORATION | 2016-08-25 | — | — | US | disclosed |
| US-9012527-B2 | Curable compositions for three-dimensional printing | XEROX CORPORATION (US) | 2015-04-21 | — | — | US | disclosed |
| US-9012527-B2 | Curable compositions for three-dimensional printing | XEROX CORPORATION (US) | 2015-04-21 | — | — | US | disclosed |
| US-20140171537-A1 | Orange Curable Ink | XEROX CORPORATION (US) | 2014-06-19 | — | — | US | disclosed |
| US-20140171537-A1 | Orange Curable Ink | XEROX CORPORATION (US) | 2014-06-19 | — | — | US | disclosed |
| US-8084637-B2 | Amide gellant compounds with aromatic end groups | XEROX CORPORATION (US) | 2011-12-27 | — | — | US | disclosed |
| US-8084637-B2 | Amide gellant compounds with aromatic end groups | XEROX CORPORATION (US) | 2011-12-27 | — | — | US | disclosed |
| US-20110263890-A1 | Amide Gellant Compounds With Aromatic End Groups | XEROX CORPORATION (US) | 2011-10-27 | — | — | US | disclosed |
| US-20110263769-A1 | Phase Change Inks Containing Amide Gellant Compounds With Aromatic End Groups | XEROX CORPORATION (US) | 2011-10-27 | — | — | US | disclosed |
| US-20110262711-A1 | CURABLE COMPOSITIONS FOR THREE-DIMENSIONAL PRINTING | XEROX CORPORATION (US) | 2011-10-27 | — | — | US | disclosed |
| US-20110263769-A1 | Phase Change Inks Containing Amide Gellant Compounds With Aromatic End Groups | XEROX CORPORATION (US) | 2011-10-27 | — | — | US | disclosed |
| US-20110263890-A1 | Amide Gellant Compounds With Aromatic End Groups | XEROX CORPORATION (US) | 2011-10-27 | — | — | US | disclosed |
| US-20110262711-A1 | CURABLE COMPOSITIONS FOR THREE-DIMENSIONAL PRINTING | XEROX CORPORATION (US) | 2011-10-27 | — | — | US | disclosed |
| US-20110262643-A1 | INK COMPOSITIONS AND METHODS | XEROX CORPORATION (US) | 2011-10-27 | — | — | US | disclosed |
| US-20110262643-A1 | INK COMPOSITIONS AND METHODS | XEROX CORPORATION (US) | 2011-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263890-A1 | Amide Gellant Compounds With Aromatic End Groups | NAT1, AGPAT2, CCNT1 | MEN1 3843/4885HPGD 3248/4885KMT2A 200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.